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Abrupt discontinuation of many pharmaceuticals is 
associated with withdrawal symptoms. Antidepressant 
drugs are associated with a group of common 
symptoms after discontinuation.1 The first cases of 
antidepressant discontinuation syndrome were 
reported for imipramine by Andersen and Christiansen 
in 1959. Since then, this phenomenon has been 
described for different families of antidepressants: 
Tricyclics, Monoamine Oxidase Inhibitors, and more 
recently, selective serotonin reuptake inhibitors. Some 
newborns exposed during pregnancy to serotonin and 
norepinephrine reuptake inhibitors or selective 
serotonin reuptake inhibitors may present, at birth, 
symptoms such as respiratory distress, cyanosis, apnea, 
seizures, feeding difficulties, vomiting, hypoglycemia, 
muscle tone changes, tremors, or irritability. This is 
related to the direct toxic effect of selective serotonin 
reuptake inhibitors and serotonin and norepinephrine 
reuptake inhibitors and is known as antidepressant 
discontinuation syndrome or serotonin syndrome. 
There are very few documented and published cases in 
the literature on newborns exposed during pregnancy 
to selective serotonin reuptake inhibitors with 
subsequent development of serotonin syndrome. 
 
CASE REPORT 
We present the case of a 5-day old female baby who was 
referred from a rural civil hospital to our clinic for 
presenting involuntary movements of the four limbs 




the baby was 3.5 kilograms. As per the medical history, 
only the mother had been taking venlafaxine treatment 
during pregnancy. There were no other perinatal 
incidents. Upon arrival at our centre, she was 
monitored with normal vital signs, and brain function 
monitoring was started by means of amplitude-
integrated electroencephalography, showing a 
continuous trace. Subsequently, a conventional 
electroencephalogram was performed, coinciding with 
frequent movements of the patient, which was 
reported as normal, without pathological graph 
elements of epileptiform morphology. Brain 
ultrasound showed no relevant alterations.  
 
Toxicity determination was performed in urine, with 
negative result. Infectious, neurometabolic, and 
hormonal examinations were performed, without 
evidence of any pathological findings. The patient had 
normal results at physical and neurological 
examination at all times. The mother had also 
encountered dizziness, lightheadedness, excessive 
sweating, irritability, dysphoria, and insomnia and 
started performing similar movements few days after 
stopping the treatment with venlafaxine that she had 
received during pregnancy, so it was suspected that the 
condition was due to a serotonin syndrome caused by 
venlafaxine withdrawal. The mother also revealed that 
she fully recovered from her withdrawal symptoms few 
hours after she was given a dose of venlafaxine by her 
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prescription. The baby was kept under observation in 
our special care unit and no intervention was started. 
Her involuntary movements persisted intermittently, 
becoming less and less frequent, giving way completely 
after one week of life. The patient was discharged 
without incident and remained asymptomatic at 
weekly and monthly follow up. 
 
DISCUSSION 
The phenomena of discontinuation of serotonin 
reuptake inhibitors have been described since first half 
of 20th century, their appearance being unusual in the 
neonatal setting. It is well recognized that babies 
exposed to antidepressants in utero may develop 
symptoms of drug withdrawal following birth. Such 
symptoms include diarrhea, vomiting, hypothermia, 
restlessness, irritability, agitation, inadequate feeding, 
insomnia, hypoglycemia, respiratory distress, altered 
muscle tone, hyper-reflexia, tremors and seizures.  
 
A urine toxicology screen when taken shortly after 
birth in symptomatic subjects can be used to exclude 
exposure to certain drugs. Venlafaxine, with 
noradrenergic and serotonergic action, is a relatively 
new antidepressant. However, in a clinical trial, Farah 
and Lauer described discontinuation episodes in some 
patients.2 Fava et al. found discontinuation symptoms 
in 78% of patients treated with sustained-release 
venlafaxine versus 28% in patients treated with 
placebo.3 The diagnosis was made after the exclusion of 
other causes of paroxysmal movements and confirmed 
when the same symptoms were observed in the mother 
after the drug was discontinued. Current evidence 
indicates that fetal exposure to selective serotonin 
reuptake inhibitors during the last trimester of 
pregnancy may lead to a neonatal behavioral 
syndrome, generally self-limiting.4 The decision to 
expose the fetus to antidepressant medications during 
pregnancy must be weighed against the risks of 
untreated maternal depression for both the mother and 
the fetus, so it should be used only if the potential 
benefits justify the risks to the fetus. Exposed newborns 
should be monitored after delivery for the direct toxic 
effects of this drug, drug discontinuation syndrome, 
and serotonin syndrome. 
 
CONCLUSION 
Discontinuation related adverse reactions are fairly 
common among antidepressant treated patients. This 
may also affect the baby in a similar way if these drugs 
are administered to the mother during pregnancy and 
abruptly stopped. Healthcare professionals should 
consider tapering the antidepressant dose gradually. 
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